RESULTS OF USING ADENO RITZ IN BENIGN PROSTATIC HYPERPLASIA IN YOUNG MEN
Article Sidebar
Main Article Content
Аннотация:
To analyze the effect of Adeno ritz at a dose of 320 mg once a day on sexual function compared to tamsulosin at a dose of 0.4 mg once, in men with lower urinary tract symptoms (LUTs) complicated by benign prostatic hyperplasia.
Ключевые слова:
Article Details
Как цитировать:
Библиографические ссылки:
Madersbachera S., Alivizatosb G., Nordlingc J. et al. EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines). European Urology. 2004; 46:547–554. DOI: 10.1016/j.eururo.2004.07.016.
McVary K.T. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther. 2007;29(3):387–398. DOI: 10.1016/S0149-2918(07)80077-4.
Van Dijk M.M., de la Rosette J.J., Michel M.C. Effects of alpha — adrenoceptor antagonists on male sexual function. Drugs, 2006;66:287–301. DOI: 10.2165/00003495–200666030–00002.
McConnell J.D., Roehrborn C.G., Bautista O.M. et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349: 2387–2398. DOI: 10.1056/NEJMoa030656.
Roehrborn C.G., Siami P., Barkin J. et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123–131. DOI: 10.1016/j.eururo.2009.09.035.
Hammarsten J., Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol. 2011;8(9):483–494. DOI: 10.1038/nrurol.2011.112.
Hennenberg M., Stief C.G., Gratzke C. Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling. Neurourol Urodyn. 2014;33(7):1074–1085. DOI: 10.1002/nau.22467.
Kamalov A. A., Takhirzade A.M. Approaches to drug treatment of patients with a high risk of progression of benign prostatic hyperplasia depending on concomitant erectile dysfunction. Urology. 2018;3:70–77. DOI: 10.18565/urology.2018.3.70-77.
Bartram W. European Union herbal monograph on Serenoa repens. European Medicines Agency; 2016.
Oelke M., Bachmann A., Descazeaud A. et al. EAU guidelines on the management of male lower urinary tract symptoms, including benign prostatic obstruction. EAU guidelines; 2013.
De la Taille A. Therapeutic Approach: The Importance of Controlling Prostatic Inflammation. European Urology Supplements. 2013;12:116–122. DOI: 10.1016/j.eursup.2013.08.003.
Vacherot F., Azzouz M., Gil-Diez-De-Medina S., Colombel M., De LaTaille A., Lefrere Belda M.-A., et al. (2000) Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) in benign prostatic hyperplasia. Prostate 45: 259–259.
Di Silverio F., Monti S., Sciarra A., Varasano P.A., Martini C., Lanzara S., et al. (1998) Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 37: 77–83.
Giuliano F. (2006) Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 97: 34–38.
Zlotta A.R., Teillac P., Raynaud J.P., Schulman C.C. (2005) Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride. Eur Urol 48: 269–276.
Debruyne F., Boyle P., Calais Da Silva F., Gillenwater J.G., Hamdy F.C., Perrin P., et al. (2004a) Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients – PERMAL study subset analysis. Eur Urol 45: 773–779.
Carraro J.C., Raynaud J.P., Koch G., Chisholm G.D., Di Silverio F., Teillac P., et al. (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29: 231–240.
Oelke, M., Bachmann, A., Descazeaud, A., Emberton, M., Gravas, S., Michel, M.C. et al. (2011) Guidelines on the treatment of non-neurogenic male LUTS. EAU online Guidelines.
Suzuki M., Ito Y., Fujino T. et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009;30 (3):271–281. DOI: 10.1038/aps.2009.1.
Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Schulman CC.
Eur Urol. 2004 Jun; 45(6):773-9; disucssion 779-80.
Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Urology. 2001 Dec; 58(6):960-4; discussion 964-5.